We hope to see you at the PRIM&R Conference in Wash DC next week. We'll be exhibiting Insight and giving 2–3 minute quick demos on the key features and capabilities for our Animal Studies and Human Studies modules. As the world evolves and modernizes, PRIM&R seeks to create a space to think holistically about the research enterprise and endeavors to achieve a shared vision of advancing ethical, responsible, and high-quality research. Insight delivers this vision, with a full suite solution for the research and innovation lifecycle, fully integrated and paperless, consolidating many point solutions into a single, unified platform for maximum efficiencies.
Stop by our double Booths #117 and check out Insight, watch a quick demo and let us showcase how Insight can automate and innovate your enterprise research and innovation programs.
We are also presenting Insight's Human Research module at a Live Presentation on Dec. 7 at 7:30 am. Our guest speaker will be Martha Jones, Vice President at Mass General Brigham. Martha is a well-known thought leader in the Human Research Affairs arena and will be speaking about her experiences as a consumer of Insight and the benefits that she and her teams have gained from using Insight.
Visit our website page at https://lnkd.in/ebj2YHJE to view what we have planned on Dec. 4 and 5.
Drop by our booths to say hello and pick up a gift!
#research #researchadministration #animalresearch #humanresearch #iacuc #irb #Researchinsight #insight #MarthaJones #ScottMcNeal #researchers
SaaS Finance | Equity Investor
3wZoetis when are you going to start selling GLP-1 (or similar) drugs for dogs & cats? Look at how much market cap Eli Lilly and Company & Novo Nordisk have added thanks to Ozempic, Wegovy, and Mounjaro. There are a lot of overweight pets and imo this stock can get to $100b market cap based on the current pipeline + add a weight-loss/diabetes drug and you can get past $200b market cap. I would look buy more of Zoetis if you missed the Eli Lilly and Company train.